Do Not Stop Hydroxychloroquine or Prednisone for SLE
You should continue both hydroxychloroquine and prednisone for your systemic lupus erythematosus treatment, as discontinuing either medication significantly increases your risk of disease flares and complications. 1, 2
Hydroxychloroquine: The Backbone of SLE Treatment
Hydroxychloroquine is FDA-approved and considered essential therapy for all SLE patients 2. The evidence strongly supports continuous use:
- Discontinuing HCQ increases flare risk by 56-130% compared to continuing treatment (hazard ratios 1.56-2.30) 1
- Even tapering to lower doses increases flare risk by 20% 1
- Abrupt discontinuation causes flares in 72.6% of patients versus 45.9% with gradual tapering 1
- HCQ prevents disease activity, reduces organ damage, decreases infections, and lowers mortality 3
The optimal dose is 200 mg daily (approximately 3-3.5 mg/kg/day), which achieves prolonged remission in 72% of patients while minimizing retinal toxicity risk 4. Doses should not exceed 5 mg/kg actual body weight to keep retinopathy risk below 2% after 10 years of use 5.
Critical Safety Point for HCQ
You need annual ophthalmologic screening to monitor for retinal toxicity, but do not stop HCQ for borderline eye findings - the goal of screening is to safely maintain this valuable medication 5.
Prednisone: Minimize but Don't Casually Discontinue
The glucocorticoid situation is more nuanced:
- Stopping prednisone increases flare rates - the CORTICOLUP trial showed higher flare rates in patients who discontinued 5 mg/day versus those who continued 1
- Meta-analyses report 24% global flare rate and 13% major flare rate after glucocorticoid withdrawal 1
- However, gradual tapering to discontinuation can be achieved without increasing flare risk if you have long-standing remission and taper slowly 1
Your target should be ≤5 mg/day prednisone (ideally 2.5 mg/day or complete discontinuation) rather than abrupt cessation 6, 3. High-dose prednisone regimens increase mortality, infection risk, and organ damage 3.
The Algorithm for Your Situation
Do not stop either medication without:
- Confirming sustained remission - You need documented low disease activity or remission over multiple consecutive visits
- Maintaining HCQ continuously - This is non-negotiable background therapy
- Tapering prednisone gradually - Only if you've been in remission, reduce by small increments over months
- Close monitoring - Increase surveillance during any taper attempt
If you're considering stopping due to side effects:
- For HCQ retinal concerns: Get proper ophthalmologic evaluation first; dose adjustment to 200 mg/day may suffice 5, 4
- For prednisone side effects: Taper gradually rather than stop abruptly, consider adding immunosuppressives (methotrexate, azathioprine, mycophenolate) or biologics (belimumab, anifrolumab) to facilitate steroid reduction 1, 7
Common Pitfalls to Avoid
- Never stop HCQ during pregnancy - it's safe and actually reduces flare risk and adverse pregnancy outcomes 8
- Don't confuse "low dose" with "unnecessary" - even 200 mg/day HCQ provides critical disease control 4
- Avoid abrupt prednisone discontinuation - this causes rebound flares even at 5 mg/day 1
- Don't stop medications based on feeling well - SLE requires continuous suppression to prevent organ damage
The 2023 EULAR guidelines emphasize that all SLE patients should receive HCQ unless contraindicated, and glucocorticoids should be minimized but not casually discontinued 1, 7.